GSK moves bioprocessing to UK from India

A focus on efficiency at a GlaxoSmithKline manufacturing plant in the UK has caught the eye of CEO Andrew Witty and prompted him to take an unusual action. He's moving biomanufacturing from India to the drug giant's facilities in Montrose, a town within Scotland's Angus region.

Witty acknowledged the cost and process-efficiency improvements at Montrose, which currently employs 280. "This is a workforce that has rolled with the punches," he says, as quoted in The Courier. The ops team "outmaneuvered" a plant closure, which appeared imminent a few years ago.

Steroid manufacturing is one operation that will return to the town. Locals are hoping that Montrose may become the chosen location for a new biopharma plant being planned by the drug giant.

- here's the story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.